235 related articles for article (PubMed ID: 17324404)
1. Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency.
Takahashi Y; Iida K; Takahashi K; Yoshioka S; Fukuoka H; Takeno R; Imanaka M; Nishizawa H; Takahashi M; Seo Y; Hayashi Y; Kondo T; Okimura Y; Kaji H; Kitazawa R; Kitazawa S; Chihara K
Gastroenterology; 2007 Mar; 132(3):938-43. PubMed ID: 17324404
[TBL] [Abstract][Full Text] [Related]
2. Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis.
Nocito A; Dahm F; Jochum W; Jang JH; Georgiev P; Bader M; Renner EL; Clavien PA
Gastroenterology; 2007 Aug; 133(2):608-18. PubMed ID: 17681180
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of growth hormone replacement therapy on liver function in adult patients with growth hormone deficiency.
Matsumoto R; Fukuoka H; Iguchi G; Nishizawa H; Bando H; Suda K; Takahashi M; Takahashi Y
Growth Horm IGF Res; 2014 Oct; 24(5):174-9. PubMed ID: 25116471
[TBL] [Abstract][Full Text] [Related]
4. GH-independent IGF-I action is essential to prevent the development of nonalcoholic steatohepatitis in a GH-deficient rat model.
Nishizawa H; Takahashi M; Fukuoka H; Iguchi G; Kitazawa R; Takahashi Y
Biochem Biophys Res Commun; 2012 Jun; 423(2):295-300. PubMed ID: 22659415
[TBL] [Abstract][Full Text] [Related]
5. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.
Javor ED; Ghany MG; Cochran EK; Oral EA; DePaoli AM; Premkumar A; Kleiner DE; Gorden P
Hepatology; 2005 Apr; 41(4):753-60. PubMed ID: 15791619
[TBL] [Abstract][Full Text] [Related]
6. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis.
Wieckowska A; Papouchado BG; Li Z; Lopez R; Zein NN; Feldstein AE
Am J Gastroenterol; 2008 Jun; 103(6):1372-9. PubMed ID: 18510618
[TBL] [Abstract][Full Text] [Related]
7. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.
Nelson A; Torres DM; Morgan AE; Fincke C; Harrison SA
J Clin Gastroenterol; 2009; 43(10):990-4. PubMed ID: 19448566
[TBL] [Abstract][Full Text] [Related]
8. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.
Ito S; Yukawa T; Uetake S; Yamauchi M
Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172
[TBL] [Abstract][Full Text] [Related]
9. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction.
Richardson MM; Jonsson JR; Powell EE; Brunt EM; Neuschwander-Tetri BA; Bhathal PS; Dixon JB; Weltman MD; Tilg H; Moschen AR; Purdie DM; Demetris AJ; Clouston AD
Gastroenterology; 2007 Jul; 133(1):80-90. PubMed ID: 17631134
[TBL] [Abstract][Full Text] [Related]
10. [Nonalcoholic steatohepatitis. Three case reports].
Eivindson MV; Hamilton-Dutoit S; Grønbaek H
Ugeskr Laeger; 2003 Mar; 165(11):1118-20. PubMed ID: 12677986
[TBL] [Abstract][Full Text] [Related]
11. [Diagnosis and treatment of adult growth hormone deficiency (aGHD) resulting from brain injury--role of aGHD].
Arita K; Hirano H; Tominaga A; Kurisu K
Brain Nerve; 2008 Dec; 60(12):1445-54. PubMed ID: 19110756
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.
Promrat K; Lutchman G; Uwaifo GI; Freedman RJ; Soza A; Heller T; Doo E; Ghany M; Premkumar A; Park Y; Liang TJ; Yanovski JA; Kleiner DE; Hoofnagle JH
Hepatology; 2004 Jan; 39(1):188-96. PubMed ID: 14752837
[TBL] [Abstract][Full Text] [Related]
13. Iron overload is associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis.
Fujita N; Miyachi H; Tanaka H; Takeo M; Nakagawa N; Kobayashi Y; Iwasa M; Watanabe S; Takei Y
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):424-32. PubMed ID: 19190144
[TBL] [Abstract][Full Text] [Related]
14. [Nonalcoholic steatohepatitis: pathogenesis and treatment].
Park SH
Korean J Hepatol; 2008 Mar; 14(1):12-27. PubMed ID: 18367854
[TBL] [Abstract][Full Text] [Related]
15. Non-alcoholic steatohepatitis.
Das K; Kar P
J Assoc Physicians India; 2005 Mar; 53():195-9. PubMed ID: 15926603
[TBL] [Abstract][Full Text] [Related]
16. Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(2):377-9. PubMed ID: 15922116
[TBL] [Abstract][Full Text] [Related]
17. Hepatic microcirculation in fatty liver disease.
Farrell GC; Teoh NC; McCuskey RS
Anat Rec (Hoboken); 2008 Jun; 291(6):684-92. PubMed ID: 18484615
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
Hyogo H; Tazuma S; Arihiro K; Iwamoto K; Nabeshima Y; Inoue M; Ishitobi T; Nonaka M; Chayama K
Metabolism; 2008 Dec; 57(12):1711-8. PubMed ID: 19013295
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis.
Satapathy SK; Sakhuja P; Malhotra V; Sharma BC; Sarin SK
J Gastroenterol Hepatol; 2007 May; 22(5):634-8. PubMed ID: 17444848
[TBL] [Abstract][Full Text] [Related]
20. Effects of adult growth hormone deficiency and growth hormone replacement on circadian rhythmicity.
White HD; Ahmad AM; Vora JP
Minerva Endocrinol; 2003 Mar; 28(1):13-25. PubMed ID: 12621360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
